ALICE

Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer. NBCG16, PI: Jon Amund Kyte.

Bay BC Ra233 Study A (16928)

A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy. Bayer 16298, PI: Bjørn Naume.

Bay BC Ra233 Study B (17096)

A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases. PI: Bjørn Naume.

BROCADE 3

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer. The AbbVie-study M12-895, PI: Hans Petter Eikesdal.

EBBA2

The EBBA (Energy Balance and Breast cancer Aspects)-II study is a randomized clinical 12 month physical activity intervention trial, including female breast cancer patients diagnosed with histologically verified invasive cancer stage I-II or with ductal carcinoma in situ (DCIS) grade 3. NBCG14, PI: Inger Thune.

I-BCT

Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting. PI: Olav Engebråten.

LYTIX

A phase I, open-label, multi-arm, multi-centre, multi-dose, dose escalation study of LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab. PI: Pål Fr. Brunsvig.

Neo-BCT-2

Breast conserving surgery (BCT) after neoadjuvant therapy for large primary breast cancer (T2-T3) with infavourable tumor-to-breast size ratio(NEO‐BCT‐2). Kun aktuell ved inklusjon i I-BCT studien. PI: Helle Skjerven.

NEOLETEXE

Presurgical treatment with letrozole and exemestane in postmenopausal patients with ER-positive, locally advanced breast cancer: an intra-patient, cross-over trial. PI: Jürgen Geisler.

PETREMAC

PErsonalized TREatment of high-risk MAmmary Cancer – the PETREMAC Trial. Positive Trial. NBCG15, PI: Hans Petter Eikesdal.

POSITIVE studien

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer. PI: Anna Sætersdal.

Skagen Trial I

Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost. PI: Ingvil Mjaaland.